Morgan Stanley upgraded Embecta (EMBC) to Equal Weight from Underweight with a price target of $20, up from $13, following the company’s ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Dynamic Technology Lab Private Ltd lessened its stake in Embecta Corp. (NASDAQ:EMBC – Free Report) by 6.4% during the 3rd ...

List today: Embecta Corp. EMBC: This medical device company has seen the Zacks Consensus Estimate for its current year ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 2: Embecta ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 ...

BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...

Embecta EMBC is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors ...